[The study of relationship between platelet function and thrombus in patients with essential thrombocythaemia]

Area of Science:

• Hematology
• Thrombosis Research
• Pharmacology

Context:

• Essential thrombocytosis (ET) is characterized by elevated platelet counts and increased risk of thrombotic events.
• Platelet activation markers, including CD62P, PAC-1, and thromboxane B2 (TXB2), are often elevated in ET patients.
• Understanding the mechanisms of thrombosis in ET is crucial for developing effective preventative and therapeutic strategies.

Purpose:

• To investigate the influence of plasma thromboxane B2 (TXB2), 6-keto-PGF1alpha, CD62P, and PAC-1 on thrombosis in patients with essential thrombocytosis (ET).
• To evaluate the efficacy of sodium ozagrel in preventing and treating thrombosis in ET patients.

Summary:

• Patients with ET exhibited significantly higher plasma levels of CD62P, PAC-1, TXB2, and 6-keto-PGF1alpha compared to healthy individuals.
• Treatment with sodium ozagrel led to a significant decrease in plasma CD62P, PAC-1, and TXB2 levels, bringing them closer to normal ranges.
• The incidence of thrombus formation was significantly lower in ET patients treated with sodium ozagrel compared to those who did not receive the treatment.

Impact:

• Sodium ozagrel effectively reduces key markers of platelet activation and the thromboxane A2/prostacyclin ratio in ET patients.
• The findings suggest that sodium ozagrel is a promising therapeutic agent for reducing thrombotic risk in essential thrombocytosis.
• This study provides evidence for the clinical utility of sodium ozagrel in managing thrombotic complications associated with ET.